Elevated insular glutamate in fibromyalgia is associated with experimental pain ClinicalTrials.gov identifier: NCT00142597.
dc.contributor.author | Harris, Richard E. | en_US |
dc.contributor.author | Sundgren, Pia C. | en_US |
dc.contributor.author | Craig, A. D. | en_US |
dc.contributor.author | Kirshenbaum, Eric | en_US |
dc.contributor.author | Sen, Ananda | en_US |
dc.contributor.author | Napadow, Vitaly | en_US |
dc.contributor.author | Clauw, Daniel J. | en_US |
dc.date.accessioned | 2009-11-06T16:49:38Z | |
dc.date.available | 2010-03-01T21:10:29Z | en_US |
dc.date.issued | 2009-10 | en_US |
dc.identifier.citation | Harris, Richard E.; Sundgren, Pia C.; Craig, A. D.; Kirshenbaum, Eric; Sen, Ananda; Napadow, Vitaly; Clauw, Daniel J. (2009). "Elevated insular glutamate in fibromyalgia is associated with experimental pain ClinicalTrials.gov identifier: NCT00142597. ." Arthritis & Rheumatism 60(10): 3146-3152. <http://hdl.handle.net/2027.42/64321> | en_US |
dc.identifier.issn | 0004-3591 | en_US |
dc.identifier.issn | 1529-0131 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/64321 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19790053&dopt=citation | en_US |
dc.description.abstract | Objective Central pain augmentation resulting from enhanced excitatory and/or decreased inhibitory neurotransmission is a proposed mechanism underlying the pathophysiology of functional pain syndromes such as fibromyalgia (FM). Multiple functional magnetic resonance imaging studies implicate the insula as a region of heightened neuronal activity in this condition. Since glutamate (Glu) is a major cortical excitatory neurotransmitter that functions in pain neurotransmission, we undertook this study to test our hypothesis that increased levels of insular Glu would be present in FM patients and that the concentration of this molecule would be correlated with pain report. Methods Nineteen FM patients and 14 age- and sex-matched pain-free controls underwent pressure pain testing and a proton magnetic resonance spectroscopy session in which the right anterior insula and right posterior insula were examined at rest. Results Compared with healthy controls, FM patients had significantly higher levels of Glu (mean ± SD 8.09 ± 0.72 arbitrary institutional units versus 6.86 ± 1.29 arbitrary institutional units; P = 0.009) and combined glutamine and Glu (i.e., Glx) (mean ± SD 12.38 ± 0.94 arbitrary institutional units versus 10.59 ± 1.48 arbitrary institutional units; P = 0.001) within the right posterior insula. No significant differences between groups were detected in any of the other major metabolites within this region ( P > 0.05 for all comparisons), and no group differences were detected for any metabolite within the right anterior insula ( P > 0.11 for all comparisons). Within the right posterior insula, higher levels of Glu and Glx were associated with lower pressure pain thresholds across both groups for medium pain (for Glu, r = −0.43, P = 0.012; for Glx, r = −0.50, P = 0.003). Conclusion Enhanced glutamatergic neurotransmission resulting from higher concentrations of Glu within the posterior insula may play a role in the pathophysiology of FM and other central pain augmentation syndromes. | en_US |
dc.format.extent | 165981 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.title | Elevated insular glutamate in fibromyalgia is associated with experimental pain ClinicalTrials.gov identifier: NCT00142597. | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Geriatrics | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor ; Dr. Harris has received consulting fees, speaking fees, and/or honoraria from Pfizer (less than $10,000). ; University of Michigan, Chronic Pain and Fatigue Research Center, 24 Frank Lloyd Wright Drive, PO Box 385, Lobby M, Ann Arbor, MI 48106 | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor ; Dr. Clauw has received consulting fees, speaking fees, and/or honoraria from Pfizer, UCB, Wyeth, and Cypress Bioscience (less than $10,000 each) and from Pierre Fabre Laboratories, Lilly, and Forest Laboratories (more than $10,000 each), as well as a one-time royalty from Lilly for the knowfibro.com Web site. | en_US |
dc.contributor.affiliationother | Barrow Neurological Institute, Phoenix, Arizona | en_US |
dc.contributor.affiliationother | Massachusetts General Hospital, Charlestown ; Dr. Napadow has received consulting fees, speaking fees, and/or honoraria from Boston University (less than $10,000). | en_US |
dc.identifier.pmid | 19790053 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/64321/1/24849_ftp.pdf | |
dc.identifier.doi | 10.1002/art.24849 | en_US |
dc.identifier.source | Arthritis & Rheumatism | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.